Technological advances in studying the human microbiome in depth have enabled the identification of microbial signatures associated with health and disease. This confirms the crucial role of microbiota in maintaining homeostasis and the host health [...]
Inmunobiota is one of the projects selected in CSIC-COCREA that seeks to develop products based on microbiota to combat infections and enhance the immune response. THE CHALLENGE Immunotherapy has improved the prognosis of lung cancer, [...]
Microviable Therapeutics, which develops oral drugs based on microbiota-derived products, hopes to soon open a financing round of more than five million euros to advance its research toward the clinical phase, according to Claudio Hidalgo, [...]
Microviable Therapeutics will be presenting at I Asturias International Meeting on Clinical Microbiology and Infectious Disease (AIMID 2022) on September 22-23. Claudio Hidalgo, CEO at Microviable, will discuss the use of “Microbiome-derived biotherapeutic products for [...]